Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp351 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Cytokine levels in the bone marrow are not just a reflection of the levels in serum: suggesting that bone marrow constitutes an independent compartment

Harslof Torben , Sorensen Lotte , Pedersen Steen , Langdahl Bente

Bone marrow is composed of cells developed within the marrow compartment as well as blood supplied from the general circulation. Bone tissue is affected by cytokines within the bone marrow.We investigated if the levels of different bone acting cytokines differ between bone marrow and blood from the peripheral circulation.Fifty-three healthy postmenopausal women participated in a study designed to evaluate the effect of rosiglitazon...

ba0003pp195 | Genetics | ECTS2014

Interactions between the effects of polymorphisms in the RANK and RANKL genes affects bone mass

Andersen Jane Dahl , Harslof Torben , Husted Lise , Langdahl Bente

Osteoporosis is a common disorder with a partly genetic pathogenesis. Interaction between RANKL and its receptor RANK is essential in bone remodeling.We therefore investigated the effect of polymorphisms in the RANK and RANKL genes and interaction between the effects on bone mineral density (BMD) and vertebral fractures.The study was a case-control study with 462 osteoporotic patients and 336 controls. Ten polymor...

ba0005p389 | Osteoporosis: treatment | ECTS2016

Hypercalcemia after discontinuation of long-term denosumab treatment

Langdahl Bente , Harslof Torben , Kaal Andreas , Rejnmark Lars , Sophie Solling Anne

Purpose: Denosumab is commonly used as an anti-resorptive agent to treat osteoporosis. After discontinuation of denosumab, however, bone resorption increases again, and the bone mass gained during therapy is lost within a year.Methods: We present a case report of asymptomatic hypoparathyroid hypercalcemia in a patient who discontinued long-term treatment with denosumab.Results: A 67-year old women with osteoporosis was treated with...

ba0005p393 | Osteoporosis: treatment | ECTS2016

Long-term high-dose resveratrol supplementation reduces bone mass and strength in rats

Juul Ornstrup Marie , Bruel Annemarie , Skovhus Thomsen Jesper , Harslof Torben , Lomholt Langdahl Bente , Bonlokke Pedersen Steen

Background: Resveratrol (RSV), a natural polyphenolic compound, stimulates osteoblasts and inhibits osteoclast activation in vitro. Conflicting results have emerged from short-term studies in rodents but a recent study in men suggests a positive effect on BMD.Aim: To evaluate effects of short- and long-term high-dose RSV supplementation on bone in immobilized and non-immobilized rats.Methods: A total of 72 female Wistar ra...

ba0005p436 | Other diseases of bone and mineral metabolism | ECTS2016

Determinants of health related quality of life in adults with osteogenesis imperfecta

Hald Jannie Dahl , Folkestad Lars , Harslof Torben , Brixen Kim , Langdahl Bente

Osteogenesis imperfecta (OI) is a systemic connective tissue caused by mutations in collagen type 1 related genes. Patients with OI suffer from multiple fractures and various degrees of growth deficiency and bone deformity. Other symptoms are early hearing loss, abnormal dental tissue and hypermobility. It is not known whether the systemic effect of a defect collagen type 1 influences the quality of life in people with OI. We aimed to investigate health related quality of life...

ba0003pp300 | Osteoporosis: treatment | ECTS2014

Resveratrol supplementation increases vBMD at the spine in obese men: a randomized controlled trial

Ornstrup Marie Juul , Harslof Torben , Kjaer Thomas Nordstrom , Paulsen Soren Kildeberg , Langdahl Bente Lomholt , Pedersen Steen Bonlokke

Background: Resveratrol (RSV) is a natural polyphenolic compound, found in fx grapes, which possesses anti-inflammatory properties. RSV inhibits osteoclast activity and promotes osteoblastogenesis in vitro. Furthermore, RSV protects against bone loss after ovarectomy and immobilization in animal models. RSV treatment of obese men for 4 weeks resulted in an increase in bone specific alkaline phosphatase (BAP).Hypothesis: Low-grade inflammation is...

ba0003pp362 | Other diseases of bone and mineral metabolism | ECTS2014

Osteogenesis imperfecta in adults: a cross sectional trial

Hald Jannie Dahl , Folkestad Lars , Andersen Jane , Harslof Torben , Lund Allan , Jens-Erik Beck Jensen , Brixen Kim , Langdahl Bente

Osteogenesis imperfecta (OI) is a hereditary disease with a generalized involvement of the connective tissue caused by collagen type 1 mutations. The clinical appearance is broad with fractures as the key symptom. Only few genotype–phenotype correlations have been established. We aim to characterize the Danish OI population thoroughly including DXA and HRpQCT, anthropometry, patient history, and genetic background.This cross-sectional study includes...

ba0001pp110 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men

Poulsen Morten Moller , Ornstrup Marie Juul , Harslof Torben , Jessen Niels , Langdahl Bente Lomholt , Richelsen Bjorn , Lunde Jorgensen Jens Otto , Pedersen Steen Bonlokke

Despite the substantial preclinical evidence for a positive effect of the polyphenolic compound resveratrol, human data are very scarce, and currently no clinical data addressing the potential impact on bone metabolism have been published. In the present study we addressed this issue by testing a panel of bone specific biomarkers in order to identify potential bone metabolic effects of resveratrol in human subjects. In a randomized, placebo-controlled, double-blinded and paral...